Drug intelligence / Profile preview

parathyroid extract

Development stage: Discontinued
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular, Subcutaneous, Intravenous

Overview

Parathyroid extract is a historical preparation derived from animal parathyroid glands, used before the development of purified or recombinant parathyroid hormone for the treatment of hypoparathyroidism and resultant hypocalcemia. The extract contains a mixture of polypeptides, including parathyroid hormone and related peptides, and acts primarily by increasing blood calcium levels through effects on bone, kidney, and gut. Its use has been replaced by purified or recombinant parathyroid hormone therapies due to variable potency, risk of immunogenicity, and impurities.

Other names: parathyroid extract

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)PTH2R (Parathyroid hormone 2 receptor)

Beyond the preview

Go deeper on parathyroid extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on parathyroid extract.

Explore the full profile